Add Yahoo as a preferred source to see more of our stories on Google. The Food and Drug Administration has reversed course and agreed to review Moderna’s application for the first mRNA-based flu ...

Add Yahoo as a preferred source to see more of our stories on Google. The U.S. Food and Drug Administration (FDA) recently informed Moderna that it would not review the company’s application for ...

In December 2025, Moderna submitted an application to the FDA to approve the first mRNA-based flu vaccine. Catherine Falls Commercial/Moment via Getty Images Ana Santos Rutschman, Villanova University ...

The FDA has agreed to review Moderna’s investigational flu vaccine for potential approval, about a week after telling the drugmaker it would not consider the application. On Feb. 10, the agency ...

The U.S. Food and Drug Administration is refusing to consider Moderna’s application for a new flu vaccine made with Nobel Prize-winning mRNA technology, the company announced Tuesday.The news is the ...

The U.S. Food and Drug Administration (FDA) recently informed Moderna that it would not review the company’s application for approval of its new flu vaccine, which is its first using mRNA technology ...

(The Conversation is an independent and nonprofit source of news, analysis and commentary from academic experts.) Ana Santos Rutschman, Villanova University (THE CONVERSATION) The Food and Drug ...

The FDA will now review Moderna’s seasonal mRNA influenza vaccine application, setting a mid-2026 decision date. In a regulatory turnaround, the FDA will now review Moderna’s seasonal mRNA flu vaccine ...

In January 2026, even before the flu vaccine refusal, Moderna’s chief executive officer said the company was scaling back on vaccine development . Finally, the FDA’s move risks fueling further ...

Moderna said today the Food and Drug Administration changed course and will review an amended application for its new flu vaccine, a week after rejecting the original submission and fueling drugmaker ...